ARVN · XBRL financial data

Arvinas financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ARVN's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue	(43)*	25	77	102	59*	189	22	42	10*	—	—	—
Revenue from contracts with customers	—	—	—	—	—	189	22	42	—	16	250	1
Research and development	95*	84	94	87	83*	91	69	65	61*	60	53	47
General and administrative	27*	24	31	76	34*	27	25	21	23*	19	24	13
Total operating expenses	122*	109	125	163	117*	117	94	86	84*	79	86	60
Operating income (loss)	(165)*	(83)	(49)	(60)	(58)*	71	(72)	(44)	(75)*	(64)	164	(59)
Interest income	12*	14	14	14	13*	12	10	9	7*	6	6	6
Interest expense	0*	0	0	0	0*	0	0	0	—	—	0	0
Other income (expense)	(0)*	0	(0)	(3)	(0)*	0	(0)	0	0*	(0)	0	(0)
Income tax expense (benefit)	2*	0	0	1	(0)*	0	(0)	0	0*	0	0	0
Net income (loss)	(155)*	(69)	(35)	(49)	(45)*	83	(61)	(35)	(67)*	(58)	169	(54)
Earnings per share, basic USD per share	(2.53)*	(0.97)	(0.49)	(0.68)	(0.63)*	1.14	(0.84)	(0.48)	—	(0.90)	2.61	(0.82)
Earnings per share, diluted USD per share	(2.53)*	(0.97)	(0.49)	(0.68)	(0.63)*	1.14	(0.84)	(0.48)	—	(0.90)	2.58	(0.82)
Weighted average shares, basic millions of shares	61*	72	72	72	72*	73	73	73	65*	64	65	65
Weighted average shares, diluted millions of shares	61*	72	72	72	72*	73	73	73	65*	64	66	65

Fiscal quarters (ARVN's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	312	88	155	85	101	81	115	102	143	87	94	88
Marketable securities	949	1,081	1,074	1,036	939	873	746	686	543	528	474	470
Accounts receivable	0	0	2	7	6	0	1	20	1	2	50	2
Prepaid and other current assets	7	8	13	13	14	17	17	12	9	9	30	24
Total current assets	1,280	1,190	1,257	1,150	1,067	980	890	826	701	631	652	588
Property and equipment, net	12	10	10	7	7	7	6	5	5	6	5	5
Right-of-use asset	3	2	2	1	9	10	9	9	8	8	7	7
Total assets	1,305	1,213	1,280	1,167	1,091	1,001	909	844	718	648	675	608
Accounts payable	18	18	23	18	13	26	17	18	24	31	8	3
Current portion of long-term debt	0	0	0	0	0	0	0	0	0	0	0	0
Total current liabilities	257	241	347	276	230	214	158	145	143	116	83	70
Long-term debt	1	1	1	1	1	1	1	0	0	0	0	0
Lease liability, non-current	1	0	0	0	7	8	8	7	7	6	6	5
Total liabilities	645	603	679	581	530	341	300	280	284	261	113	94
Accumulated deficit	(1,333)	(1,402)	(1,437)	(1,487)	(1,532)	(1,449)	(1,510)	(1,545)	(1,612)	(1,670)	(1,501)	(1,555)
Total stockholders' equity	660	610	600	586	562	660	609	564	434	387	562	514
Total liabilities and equity	1,305	1,213	1,280	1,167	1,091	1,001	909	844	718	648	675	608
Common shares outstanding (cover page) millions of shares	68	68	69	69	69	73	73	64	64	65	65	65

Fiscal quarters (ARVN's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(155)*	(69)	(35)	(49)	(45)*	83	(61)	(35)	(67)*	(58)	169	(54)
Stock-based compensation	17*	19	22*	25*	23*	15	10*	10*	9*	12	6*	6*
Net cash from operating activities	(83)*	(98)	50*	(128)*	(84)*	(89)	(95)*	(59)*	(30)*	(69)	(48)*	(10)*
Purchases of property and equipment	0*	0	1*	1*	0*	0	1*	0*	0*	1	0*	(0)*
Net cash from investing activities	(54)*	(128)	13*	51*	99*	70	129*	64*	146*	14	55*	4*
Share repurchases	year only	—	—	—	0*	—	—	—	74*	—	—	—
Repayments of long-term debt	0*	0	0*	0*	0*	0	0*	0*	0*	0	0*	0*
Net cash from financing activities	335*	2	3*	2*	1*	(0)	1*	(18)*	(74)*	(0)	0*	0*
Net change in cash	198*	(224)	67*	(75)*	15*	(20)	34*	(13)*	41*	(56)	7*	(6)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Arvinas	88	0.5	(10)*	65.5M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
Arbutus Biopharma	19	1	(6)*	197.8M	15.4 quarters	Q2 FY26 10-QJun 30, 2026
aTYR PHARMA	16	not reported	(9.4)*	98.1M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Zevra Therapeutics	122	38	10*	59.5M	—	Q3 FY26 10-QSep 30, 2026
Theravance Biopharma	220	21	(7)*	51.9M	55.7 quarters	Q2 FY26 10-QJun 30, 2026
Myriad Genetics	115	191	(8.3)*	95.6M	13.9 quarters	Q2 FY26 10-QJun 30, 2026
Kura Oncology	70	21	(63)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
KalVista Pharmaceuticals	214	41	(14)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026
CytoDyn	16	not reported	(7.7)	1.5B	2.1 quarters	Q1 FY27 10-QAug 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.